US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Zenas BioPharma Inc.

22.16

+0.70003.26%

Volume:21.28K

Turnover:460.77K

Market Cap:1.38B

PE:-2.63

High:22.20

Open:21.50

Low:21.50

Close:21.46

52wk High:44.60

52wk Low:6.11

Shares:62.37M

Float Shares:39.84M

Volume Ratio:0.27

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-8.4400

EPS(LYR):-8.4448

ROE:-136.22%

ROA:-35.06%

PB:5.71

PE(LYR):-2.62

Loading ...

Overview Company News Filings

Zenas BioPharma price target lowered to $41 from $43 at Citi

IPO-Related Securities Class Action Poses Ongoing Financial and Operational Risks for Zenas BioPharma

Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma Inc. Announces Annual Stockholders Meeting

Earnings Flash (ZBIO) Zenas BioPharma Posts Q4 Net Loss $4.54 a Share

MT Newswires Live

Zenas BioPharma Q4 EPS $(4.54) Down From $(1.26) YoY

Zenas BioPharma Q4 net loss rose 357% to USD 240.44 million

Press Release: Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Zenas Biopharma Inc expected to post a loss of $1.03 a share - Earnings Preview

Zenas BioPharma Grants Inducement Stock Options and RSUs to New Hires

Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma added to Best Ideas List at Wedbush

Why Zenas BioPharma (ZBIO) Is Up 17.4% After Positive Phase 2 Obexelimab MS Data And What's Next

Simply Wall St.

Director Patricia L. Allen Reports Acquisition of Zenas Biopharma Common Shares

Zenas Biopharma Launches Amended Short-Term Incentive Plan for Employees

Evercore ISI Reaffirms Their Buy Rating on Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.

Zenas Biopharma Reports Phase 2 MoonStone Trial Shows Obexelimab Significantly Reduces MS Lesions

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ZBIO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":22.16,"timestamp":1775483004826,"preClose":21.46,"halted":0,"volume":21279,"delay":0,"changeRate":0.03261882572227397,"floatShares":39841600,"shares":62371044,"eps":-8.44,"marketStatus":"Trading","change":0.7,"latestTime":"04-06 09:43:33 EDT","open":21.5,"high":22.2,"low":21.5,"amount":460769.84834399994,"amplitude":0.032619,"askPrice":22.25,"askSize":100,"bidPrice":21.81,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-8.44,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1775505600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":21.46,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":21.5,"preClose":21.46,"latestTime":"08:49 EDT","volume":218,"amount":4737.870082,"timestamp":1775479752352,"change":0.04,"changeRate":0.001864,"amplitude":0.027213},"postHourTrading":{"tag":"盘后","latestPrice":21.04,"preClose":21.46,"latestTime":"19:44 EDT","volume":15868,"amount":340436.44,"timestamp":1775173464847,"change":-0.42,"changeRate":-0.019571,"amplitude":0.019571},"volumeRatio":0.273324,"impliedVol":0.7851,"impliedVolPercentile":0.2881},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","floatShares":39841600,"roa":"-35.06%","roe":"-136.22%","lyrEps":-8.444814,"volumeRatio":0.273324,"shares":62371044,"dividePrice":0,"high":22.2,"amplitude":0.032619,"preClose":21.46,"low":21.5,"week52Low":6.11,"pbRate":"5.71","psRate":"138.21","week52High":44.6,"institutionHeld":0,"latestPrice":22.16,"eps":-8.44,"divideRate":0,"volume":21279,"delay":0,"ttmEps":-8.44,"open":21.5,"prevYearClose":36.31,"prevWeekClose":21.46,"prevMonthClose":19.55,"prevQuarterClose":19.55,"fiveDayClose":18.21,"twentyDayClose":25.28,"sixtyDayClose":16.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-16","symbol":"ZBIO","fiscalQuarterEnding":"2025/12","expectedEps":-1.22,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1773633600000,"reportTimeType":"pre","actualEps":-4.54},{"market":"US","date":"2025-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/09","expectedEps":-0.87,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-1.22},{"market":"US","date":"2025-08-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/06","expectedEps":-1.02,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-1.25},{"market":"US","date":"2025-05-15","symbol":"ZBIO","fiscalQuarterEnding":"2025/03","expectedEps":-1.15,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.8},{"market":"US","date":"2024-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2024/09","expectedEps":13,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-5.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.625,"buy":0.25,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.625,"analysts":8,"updateTime":1767758400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZBIO","date":"2026-04-02","current":-2.625592,"percent":0.615979,"low":-19.592941,"twenty":-9.752191,"median":-4.02768,"eighty":-2.54367,"high":-1.802568,"avg":-5.746371,"sd":4.033237,"marketCap":1211125146},"quantilePoints":[{"date":"2024-09-13","current":-8.364044,"twenty":-11.189626,"median":-10.130033,"eighty":-9.07044,"marketCap":457989962},{"date":"2024-09-20","current":-12.731934,"twenty":-12.968841,"median":-12.731934,"eighty":-9.523082,"marketCap":697162515},{"date":"2024-09-27","current":-12.564791,"twenty":-13.484804,"median":-12.909978,"eighty":-12.029776,"marketCap":688010267},{"date":"2024-10-04","current":-14.275075,"twenty":-13.747873,"median":-12.811872,"eighty":-12.31335,"marketCap":781660299},{"date":"2024-10-11","current":-13.008553,"twenty":-13.941177,"median":-13.027627,"eighty":-12.397648,"marketCap":712309358},{"date":"2024-10-18","current":-16.373229,"twenty":-14.273549,"median":-13.29848,"eighty":-12.477586,"marketCap":896548905},{"date":"2024-10-25","current":-17.845752,"twenty":-15.022781,"median":-13.503182,"eighty":-12.59822,"marketCap":977179818},{"date":"2024-10-31","current":-16.022265,"twenty":-16.022265,"median":-13.891034,"eighty":-12.731934,"marketCap":877331175},{"date":"2024-11-08","current":-15.961228,"twenty":-15.961228,"median":-14.267446,"eighty":-12.811872,"marketCap":873988961},{"date":"2024-11-15","current":-6.06727,"twenty":-16.022265,"median":-14.202594,"eighty":-12.564791,"marketCap":782495852},{"date":"2024-11-22","current":-3.382919,"twenty":-15.961228,"median":-13.807463,"eighty":-11.896022,"marketCap":436298426},{"date":"2024-11-29","current":-3.729636,"twenty":-15.955124,"median":-13.496851,"eighty":-6.578437,"marketCap":481014835},{"date":"2024-12-06","current":-3.402361,"twenty":-15.898664,"median":-13.178717,"eighty":-4.851473,"marketCap":438805888},{"date":"2024-12-13","current":-2.997318,"twenty":-15.744546,"median":-13.008553,"eighty":-3.729636,"marketCap":386567092},{"date":"2024-12-20","current":-3.162575,"twenty":-15.636205,"median":-12.771903,"eighty":-3.606503,"marketCap":407880521},{"date":"2024-12-27","current":-3.256545,"twenty":-15.585849,"median":-12.510288,"eighty":-3.394584,"marketCap":419999921},{"date":"2025-01-03","current":-2.91955,"twenty":-15.427152,"median":-12.339512,"eighty":-3.24488,"marketCap":376537243},{"date":"2025-01-10","current":-3.007039,"twenty":-15.189107,"median":-10.412935,"eighty":-3.188498,"marketCap":387820823},{"date":"2025-01-17","current":-2.520987,"twenty":-15.022781,"median":-6.676265,"eighty":-3.159983,"marketCap":325134267},{"date":"2025-01-24","current":-2.715408,"twenty":-14.870188,"median":-6.06727,"eighty":-3.071846,"marketCap":350208890},{"date":"2025-01-31","current":-2.469142,"twenty":-14.351372,"median":-4.794107,"eighty":-2.968155,"marketCap":318447701},{"date":"2025-02-07","current":-2.54367,"twenty":-14.313224,"median":-3.888412,"eighty":-2.841781,"marketCap":328059640},{"date":"2025-02-14","current":-2.313605,"twenty":-14.275075,"median":-3.716674,"eighty":-2.653842,"marketCap":298388004},{"date":"2025-02-21","current":-2.530708,"twenty":-14.268972,"median":-3.643766,"eighty":-2.622086,"marketCap":326387998},{"date":"2025-02-28","current":-2.141867,"twenty":-14.163683,"median":-3.476889,"eighty":-2.54367,"marketCap":276238754},{"date":"2025-03-07","current":-2.35573,"twenty":-14.007233,"median":-3.332693,"eighty":-2.517747,"marketCap":303820838},{"date":"2025-03-14","current":-2.324434,"twenty":-13.840892,"median":-3.246824,"eighty":-2.465902,"marketCap":364908203},{"date":"2025-03-21","current":-2.26852,"twenty":-13.569102,"median":-3.188498,"eighty":-2.360915,"marketCap":356130342},{"date":"2025-03-28","current":-2.138053,"twenty":-13.499383,"median":-3.165816,"eighty":-2.351842,"marketCap":335648668},{"date":"2025-04-04","current":-2.076814,"twenty":-13.408148,"median":-3.159335,"eighty":-2.284767,"marketCap":326034820},{"date":"2025-04-11","current":-1.80523,"twenty":-13.315978,"median":-3.071846,"eighty":-2.26652,"marketCap":283399498},{"date":"2025-04-17","current":-2.21793,"twenty":-13.154764,"median":-2.997318,"eighty":-2.257224,"marketCap":348188468},{"date":"2025-04-25","current":-2.657256,"twenty":-13.051602,"median":-2.943853,"eighty":-2.261324,"marketCap":417157373},{"date":"2025-05-02","current":-3.077944,"twenty":-13.023813,"median":-2.968155,"eighty":-2.26639,"marketCap":483200324},{"date":"2025-05-09","current":-2.4756,"twenty":-13.008271,"median":-2.943853,"eighty":-2.269325,"marketCap":388639550},{"date":"2025-05-16","current":-2.503456,"twenty":-12.890356,"median":-2.890387,"eighty":-2.270833,"marketCap":407464932},{"date":"2025-05-23","current":-2.942974,"twenty":-12.763909,"median":-2.866084,"eighty":-2.272453,"marketCap":479001383},{"date":"2025-05-30","current":-2.570283,"twenty":-12.665077,"median":-2.835832,"eighty":-2.278934,"marketCap":418341820},{"date":"2025-06-06","current":-2.470042,"twenty":-12.521189,"median":-2.721889,"eighty":-2.297829,"marketCap":402026489},{"date":"2025-06-13","current":-2.90956,"twenty":-12.426717,"median":-2.835832,"eighty":-2.31327,"marketCap":473562940},{"date":"2025-06-20","current":-2.392933,"twenty":-12.365673,"median":-2.76689,"eighty":-2.315238,"marketCap":389476234},{"date":"2025-06-27","current":-2.608837,"twenty":-12.215932,"median":-2.714219,"eighty":-2.322158,"marketCap":424616947},{"date":"2025-07-03","current":-2.577994,"twenty":-11.896022,"median":-2.691086,"eighty":-2.323707,"marketCap":419596845},{"date":"2025-07-11","current":-3.102331,"twenty":-8.929847,"median":-2.679496,"eighty":-2.324434,"marketCap":504938576},{"date":"2025-07-18","current":-3.387633,"twenty":-8.364044,"median":-2.699206,"eighty":-2.336288,"marketCap":551374518},{"date":"2025-07-25","current":-4.194702,"twenty":-6.676265,"median":-2.718649,"eighty":-2.349239,"marketCap":682733850},{"date":"2025-08-01","current":-4.037914,"twenty":-6.187126,"median":-2.829882,"eighty":-2.35573,"marketCap":657214999},{"date":"2025-08-08","current":-3.804019,"twenty":-6.06727,"median":-2.865865,"eighty":-2.35573,"marketCap":619145893},{"date":"2025-08-15","current":-3.987237,"twenty":-5.542498,"median":-2.90956,"eighty":-2.36209,"marketCap":705768845},{"date":"2025-08-22","current":-4.02768,"twenty":-4.889717,"median":-2.928692,"eighty":-2.362211,"marketCap":712927599},{"date":"2025-08-29","current":-3.868286,"twenty":-4.698498,"median":-2.950685,"eighty":-2.372371,"marketCap":684713689},{"date":"2025-09-05","current":-4.039575,"twenty":-4.396216,"median":-2.982091,"eighty":-2.374493,"marketCap":715033114},{"date":"2025-09-12","current":-4.798483,"twenty":-4.881439,"median":-2.99503,"eighty":-2.389351,"marketCap":849365013},{"date":"2025-09-19","current":-4.629572,"twenty":-4.881439,"median":-3.063777,"eighty":-2.399463,"marketCap":819466690},{"date":"2025-09-26","current":-4.429735,"twenty":-4.835595,"median":-3.074895,"eighty":-2.402603,"marketCap":784094028},{"date":"2025-10-03","current":-4.984046,"twenty":-4.911724,"median":-3.083269,"eighty":-2.409912,"marketCap":882211057},{"date":"2025-10-10","current":-6.604159,"twenty":-5.180553,"median":-3.135974,"eighty":-2.413574,"marketCap":1168982288},{"date":"2025-10-17","current":-5.759607,"twenty":-5.320916,"median":-3.162575,"eighty":-2.420654,"marketCap":1019490677},{"date":"2025-10-24","current":-5.949928,"twenty":-5.76722,"median":-3.174048,"eighty":-2.42495,"marketCap":1053178928},{"date":"2025-10-31","current":-9.035303,"twenty":-6.083769,"median":-3.188498,"eighty":-2.432369,"marketCap":1599311910},{"date":"2025-11-07","current":-9.81546,"twenty":-6.198298,"median":-3.245204,"eighty":-2.444339,"marketCap":1737405107},{"date":"2025-11-14","current":-10.08009,"twenty":-6.457611,"median":-3.282468,"eighty":-2.446909,"marketCap":1914199059},{"date":"2025-11-21","current":-9.848299,"twenty":-7.258864,"median":-3.371139,"eighty":-2.451734,"marketCap":1870182143},{"date":"2025-11-28","current":-10.976161,"twenty":-8.972029,"median":-3.394997,"eighty":-2.453948,"marketCap":2084362015},{"date":"2025-12-05","current":-10.772637,"twenty":-9.459248,"median":-3.515773,"eighty":-2.459247,"marketCap":2045713016},{"date":"2025-12-12","current":-11.366249,"twenty":-9.83041,"median":-3.643766,"eighty":-2.466418,"marketCap":2158439264},{"date":"2025-12-19","current":-9.913314,"twenty":-9.980024,"median":-3.678075,"eighty":-2.469682,"marketCap":1882528351},{"date":"2025-12-26","current":-12.202958,"twenty":-10.134363,"median":-3.729636,"eighty":-2.472265,"marketCap":2317329596},{"date":"2026-01-02","current":-10.263827,"twenty":-10.232168,"median":-3.760324,"eighty":-2.476253,"marketCap":1949090517},{"date":"2026-01-09","current":-4.638651,"twenty":-10.207521,"median":-3.79333,"eighty":-2.479511,"marketCap":880875114},{"date":"2026-01-16","current":-5.633657,"twenty":-10.159019,"median":-3.831007,"eighty":-2.483289,"marketCap":1069825778},{"date":"2026-01-23","current":-5.766513,"twenty":-10.142278,"median":-3.88256,"eighty":-2.488034,"marketCap":1095054986},{"date":"2026-01-30","current":-5.902195,"twenty":-10.122491,"median":-3.950232,"eighty":-2.490604,"marketCap":1120820986},{"date":"2026-02-06","current":-5.938943,"twenty":-10.119664,"median":-3.975342,"eighty":-2.498305,"marketCap":1127799277},{"date":"2026-02-13","current":-7.380571,"twenty":-10.08009,"median":-4.008147,"eighty":-2.503456,"marketCap":1401563024},{"date":"2026-02-20","current":-7.637803,"twenty":-9.946669,"median":-4.026371,"eighty":-2.50452,"marketCap":1450411065},{"date":"2026-02-27","current":-7.451239,"twenty":-9.897484,"median":-4.035344,"eighty":-2.514003,"marketCap":1414982815},{"date":"2026-03-06","current":-7.140299,"twenty":-9.857345,"median":-4.041954,"eighty":-2.520051,"marketCap":1355935733},{"date":"2026-03-13","current":-6.925469,"twenty":-9.824447,"median":-4.068124,"eighty":-2.528764,"marketCap":1315139567},{"date":"2026-03-20","current":-3.549457,"twenty":-9.816065,"median":-4.041954,"eighty":-2.535893,"marketCap":1340761298},{"date":"2026-03-27","current":-3.365681,"twenty":-9.764845,"median":-4.035344,"eighty":-2.542374,"marketCap":1271342335},{"date":"2026-04-02","current":-3.206266,"twenty":-9.752191,"median":-4.02768,"eighty":-2.54367,"marketCap":1211125146}],"updateTime":1775483013559},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZBIO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620842871","title":"Zenas BioPharma price target lowered to $41 from $43 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2620842871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620842871?lang=en_us&edition=fundamental","pubTime":"2026-03-17 17:55","pubTimestamp":1773741354,"startTime":"0","endTime":"0","summary":"Citi lowered the firm’s price target on Zenas BioPharma (ZBIO) to $41 from $43 and keeps a Buy rating on the shares. The firm updated the company’s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-price-target-lowered-to-41-from-43-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-price-target-lowered-to-41-from-43-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620432534","title":"IPO-Related Securities Class Action Poses Ongoing Financial and Operational Risks for Zenas BioPharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2620432534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620432534?lang=en_us&edition=fundamental","pubTime":"2026-03-17 14:00","pubTimestamp":1773727227,"startTime":"0","endTime":"0","summary":"Zenas BioPharma, Inc. (ZBIO) has disclosed a new risk, in the Litigation & Legal Liabilities category. Securities class action litigation represent...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ipo-related-securities-class-action-poses-ongoing-financial-and-operational-risks-for-zenas-biopharma?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ipo-related-securities-class-action-poses-ongoing-financial-and-operational-risks-for-zenas-biopharma?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620497345","title":"Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620497345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620497345?lang=en_us&edition=fundamental","pubTime":"2026-03-17 06:01","pubTimestamp":1773698504,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA43MCV2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620497659","title":"Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620497659","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620497659?lang=en_us&edition=fundamental","pubTime":"2026-03-17 06:01","pubTimestamp":1773698460,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., March  16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256797/0/en/Zenas-BioPharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619468256","title":"Zenas BioPharma Inc. Announces Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468256","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468256?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:27","pubTimestamp":1773664022,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL87tDtc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619163457","title":"Earnings Flash (ZBIO) Zenas BioPharma Posts Q4 Net Loss $4.54 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2619163457","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619163457?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:23","pubTimestamp":1773660236,"startTime":"0","endTime":"0","summary":"Earnings Flash (ZBIO) Zenas BioPharma Posts Q4 Net Loss $4.54 a Share","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619457153","title":"Zenas BioPharma Q4 EPS $(4.54) Down From $(1.26) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2619457153","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619457153?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:22","pubTimestamp":1773660136,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(4.54) per share. This is a 260.32 percent decrease over losses of $(1.26) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51264898/zenas-biopharma-q4-eps-4-54-down-from-1-26-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619452190","title":"Zenas BioPharma Q4 net loss rose 357% to USD 240.44 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2619452190","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619452190?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:01","pubTimestamp":1773658919,"startTime":"0","endTime":"0","summary":"Zenas published a fourth-quarter and full-year 2025 earnings press release. For FY 2025, Zenas reported total revenue of USD 10 million and a net loss of USD 377.74 million. In Q4 2025, R&D expense rose 13.22% to USD 55.72 million, driven by higher personnel costs and increased orelabrutinib clinical and regulatory costs, partly offset by lower obexelimab clinical and manufacturing costs. Q4 2025 net loss was USD 240.44 million, and acquired in-process R&D expense was USD 166.67 million related to the InnoCare licensing deal for orelabrutinib, ZB021 and ZB022. Zenas ended 2025 with cash, cash equivalents and investments of USD 360.46 million and said it expects to submit an obexelimab BLA for IgG4-RD to the FDA in Q2 2026 and report topline Phase 2 SunStone results in SLE in Q4 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for info","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL9zyh50:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619529024","title":"Press Release: Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2619529024","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619529024?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:01","pubTimestamp":1773658860,"startTime":"0","endTime":"0","summary":"- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results -. - Topline results of the global Phase 2 SunStone trial of obexelimab in SLE expected in Q4 2026 -. - New, half-life extended anti-CD-19 and Fc<GAMMA>RIIb mAb  progressing toward clinical development -. - Global orelabrutinib Phase 3 trial for primary progressive multiple sclerosis  ongoing; global Phase 3 trial for non-active secondary progressive MS expected to be initiated in Q1 2026 -. - Oral, IL-17AA/AF inhibitor  Phase 1 trial expected to be initiated in 2Q 2026 with initial clinical data by year-end -. obexelimab for the treatment of Immunoglobulin G4-Related Disease","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875169.SGD","LU1244550221.USD","LU1244550494.USD","IE00BZ1G4Q59.USD","LU1720051017.SGD","LU1668664300.SGD","BK4534","BK4516","LU0557290698.USD","LU2357305700.SGD","LU1548497426.USD","LU0225283273.USD","LU1732799900.SGD","LU0006306889.USD","BK4504","LU1989772840.SGD","LU0320765646.SGD","BK4585","LU0528227936.USD","LU2089283258.USD","LU2023251221.USD","BK4588","LU1989772923.USD","LU0912757837.SGD","LU0882574139.USD","SOFR","LU2089284900.SGD","LU1732800096.USD","SLE","LU0267386448.USD","IND","BK4581","LU0314104364.USD","LU1720051108.HKD","LU1791710400.SGD","LU0234570918.USD","MAA","LU1363072403.SGD","LU1074936037.SGD","LU0971096721.USD","BK4139","LU2347655156.SGD","LU2133065610.SGD","LU2111349929.HKD","LU0098860793.USD","ZBIO","LU0158827948.USD","LU1791710582.SGD","LU0106261372.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617684702","title":"Zenas Biopharma Inc  expected to post a loss of $1.03 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2617684702","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617684702?lang=en_us&edition=fundamental","pubTime":"2026-03-06 19:26","pubTimestamp":1772796365,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc  expected to post a loss of $1.03 a share - Earnings Preview Zenas Biopharma Inc ZBIO.OQ ZBIO.O is expected to  show a rise in quarterly revenue when it reports  results on March 9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL8N3ZU0Z9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613297658","title":"Zenas BioPharma Grants Inducement Stock Options and RSUs to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2613297658","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613297658?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:15","pubTimestamp":1771622108,"startTime":"0","endTime":"0","summary":"Zenas BioPharma granted inducement equity awards to newly hired employees, consisting of non-qualified stock options covering 35,700 shares and 53,625 restricted stock units. The options have a 10-year term, an exercise price of $26.77 per share, and vest over four years with 25% vesting after one year and the remainder in 36 monthly installments; the RSUs vest in four equal installments on Feb. 15 of 2027, 2028, 2029 and 2030, subject to continued service.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on February 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDLb4kY2h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","NDAQ","BK4585","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210150020.SGD","IE00BKPKM429.USD","BK4139","BK4112","SG9999014021.USD","ZBIO","LU2095319765.USD","SG9999014013.SGD","LU0314104364.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613297504","title":"Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613297504","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613297504?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:15","pubTimestamp":1771622100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nTUA6NDPWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613290902","title":"Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613290902","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613290902?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:15","pubTimestamp":1771622100,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Feb.  20, 2026  (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/20/3242153/0/en/Zenas-BioPharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612448877","title":"Zenas BioPharma added to Best Ideas List at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2612448877","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612448877?lang=en_us&edition=fundamental","pubTime":"2026-02-18 19:55","pubTimestamp":1771415742,"startTime":"0","endTime":"0","summary":"Wedbush analyst Martin Fan is adding Outperform-rated Zenas BioPharma (ZBIO) to the Wedbush Best Ideas List as the firm sees a buying opportunity f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-added-to-best-ideas-list-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-added-to-best-ideas-list-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611483606","title":"Why Zenas BioPharma (ZBIO) Is Up 17.4% After Positive Phase 2 Obexelimab MS Data And What's Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2611483606","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611483606?lang=en_us&edition=fundamental","pubTime":"2026-02-16 20:20","pubTimestamp":1771244420,"startTime":"0","endTime":"0","summary":"In early February 2026, Zenas BioPharma reported Phase 2 MoonStone trial data showing obexelimab met its primary endpoint in Relapsing Multiple Sclerosis, with a highly statistically significant reduction in new gadolinium-enhancing T1 lesions and a safety profile consistent with prior studies.\nAn interesting aspect for investors is that obexelimab reduced markers of neuroaxonal injury and maintained stable disability scores through 24 weeks, hinting at potentially meaningful disease control...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/why-zenas-biopharma-zbio-is-up-174-after-positive-phase-2-ob","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/why-zenas-biopharma-zbio-is-up-174-after-positive-phase-2-ob","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4581","LU0234570918.USD","LU1791710582.SGD","LU1989772923.USD","LU1363072403.SGD","LU0912757837.SGD","BK4504","LU1074936037.SGD","LU0267386448.USD","ZBIO","LU0225283273.USD","LU0795875169.SGD","LU2089283258.USD","LU0106831901.USD","LU2133065610.SGD","LU1244550221.USD","LU0158827781.USD","LU0882574139.USD","IE00BZ1G4Q59.USD","BK4127","LU2111349929.HKD","LU1244550494.USD","BK4534","LU1244550577.SGD","LU2271345857.HKD","LU0098860793.USD","LU0006306889.USD","LU1732800096.USD","BK4516","IE00BKVL7J92.USD","LU1791710400.SGD","LU0314104364.USD","LU1720051108.HKD","LU1720051017.SGD","LU1548497426.USD","LU2089284900.SGD","LU0528227936.USD","LU0158827948.USD","LU0320765646.SGD","LU1162221912.USD","LU0106261372.USD","LU2028103732.USD","LU1668664300.SGD","LU2357305700.SGD","BK4588","LU2347655156.SGD","BK4585","LU0795875086.SGD","LU0557290698.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611195714","title":"Director Patricia L. Allen Reports Acquisition of Zenas Biopharma Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611195714","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611195714?lang=en_us&edition=fundamental","pubTime":"2026-02-14 06:07","pubTimestamp":1771020427,"startTime":"0","endTime":"0","summary":"Patricia L. Allen, a director of Zenas Biopharma Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL3yfW8j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Patricia L. Allen Reports Acquisition of Zenas Biopharma Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611619544","title":"Zenas Biopharma Launches Amended Short-Term Incentive Plan for Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2611619544","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611619544?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:59","pubTimestamp":1771019941,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc. has announced the approval of its Amended and Restated Short-Term Incentive Plan, effective January 1, 2026. The plan provides regular full- and part-time employees with the opportunity to earn annual discretionary cash bonuses based on company performance and individual achievement of specified goals. The plan is administered by the Board of Directors for executives and by the CEO and executive leadership team for other employees. All payouts are subject to review and approval by the administrators, and payments will be made no later than March 15 following the end of each calendar year. Employees must be employed through the payment date to receive any award. The company retains the right to amend or discontinue the plan at any time.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL6ntyDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611157124","title":"Evercore ISI Reaffirms Their Buy Rating on Zenas BioPharma, Inc. (ZBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611157124","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611157124?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:17","pubTimestamp":1770988635,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Cory Kasimov maintained a Buy rating on Zenas BioPharma, Inc. yesterday and set a price target of $55.00. Kasimov covers the H...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-reaffirms-their-buy-rating-on-zenas-biopharma-inc-zbio-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-reaffirms-their-buy-rating-on-zenas-biopharma-inc-zbio-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610364090","title":"Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2610364090","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610364090?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:52","pubTimestamp":1770727920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2026 07:52 ET (12:52 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610637914","title":"Zenas Biopharma Reports Phase 2 MoonStone Trial Shows Obexelimab Significantly Reduces MS Lesions","url":"https://stock-news.laohu8.com/highlight/detail?id=2610637914","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610637914?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:05","pubTimestamp":1770638712,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc. announced results from the Phase 2 MoonStone trial of obexelimab in patients with Relapsing Multiple Sclerosis . The data were presented in a late-breaking oral session at the ACTRIMS Forum 2026. The study met its primary endpoint, demonstrating a 95% relative reduction in new gadolinium-enhancing T1 lesions compared to placebo over weeks 8 and 12. Obexelimab was reported to be well tolerated, with no new safety signals observed. Additional 24-week data indicated robust and durable activity of obexelimab. The company is also advancing orelabrutinib in global Phase 3 trials for Primary Progressive Multiple Sclerosis and plans to initiate a Phase 3 trial in non-active Secondary Progressive Multiple Sclerosis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL4F36Nr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","IE00BKPKM429.USD","NDAQ","IE00BGHQF748.EUR","BK4585","BK4139","LU2210149790.SGD","SG9999014013.SGD","BK4112","LU2210150020.SGD","LU0314104364.USD","LU2095319765.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":135,"code":"91000000","status":"200"}]}}